MedTrace Logo

A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL

NCT05883709 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2023-06-01

No results posted yet for this study

Summary

To evaluate the real-world efficacy of Tafasitamab combined with Lenalidomide base regimen in patients with relapsed or refractory DLBCL, with objective response rate as the primary end point.

Conditions

  • Diffuse Large B-cell Lymphoma

Interventions

DRUG

Tafasitamab Injection

The combination of Tafasitamab and lenalidomide based treatment was selected according to the specific conditions of patients

Sponsors & Collaborators

  • Zhao Weili

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2023-12-30
Completion
2024-12-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05883709 on ClinicalTrials.gov